

Dated- 24.01.2025

BSE LIMITED

Corporate Relations Department Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai-400001

Scrip code: 543264

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Listing Department

Exchange Plaza, 5th Floor, Plot no. C/1

G Block, Bandra Kurla Complex, Bandra (E)

Mumbai-400051

Scrip Code: NURECA

<u>Subject: Outcome of Board Meeting under Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015</u>

Dear Sir/Madam,

We wish to inform you that the Board of Directors of the Company at the meeting held today i.e. January 24, 2025 have:

- 1. approved the unaudited standalone and consolidated Financial Results of the Company for the third quarter and nine months ended on December 31, 2024.
 - Copies of unaudited standalone and consolidated Financial Results along with Limited Review Reports are enclosed herewith.
- authorised the Management Committee of the Board to conduct the Postal Ballot for seeking shareholders' approval for the appointment of Dr. K K Bhasin and Dr. Rupinder Tewari as Independent Directors of the Company w.e.f. January 1, 2025. The Management Committee has also been authorized to finalize the cut-off date for eligibility of shareholders to participate in the Postal Ballot, the e-voting period and other matters incidental thereto.
- 3. approved the appointment of Ms. Nishu Kansal as Company Secretary and Compliance Officer of the Company w.e.f. February 1, 2025.

Ms. Nishu Kansal, aged 38 years, is a qualified Company Secretary (CS), CA-Inter, and B.Com (Hons.) with over a decade of experience in Corporate Laws, Governance and Compliance Management. She has confirmed that she is not related to any director or Key Managerial Personnel (KMP) of the Company and does not hold any shares of the Company.

4. took note of the resignation of Ms. Chetna Anand as Company Secretary and Compliance Officer of the Company, effective from the close of business hours on January 24, 2025.

A copy of her resignation letter is attached herewith.

The Board Meeting commenced at 4:00 PM and concluded at 5:45 PM.

This is for your kind information and records please.

Thanking You,

Yours Sincerely,
For Nureca Limited

(Chetna Anand)
Company Secretary & Compliance Officer

January 24, 2025

To

The Board of Directors
Nureca Limited
Corporate Office: SCO 6-7-8,
Sector 9-D,
Chandigarh – 160009

Sub: Resignation from the Position of Company Secretary & Compliance Officer

Respected Sir/Ma'am,

I hereby tender my resignation from the post of Company Secretary and Compliance Officer due to personal reasons. I request you to kindly relieve me from my duties with immediate effect.

I am deeply grateful for the trust and opportunities that the Management and the Organization have provided me throughout my tenure.

I wish the company continued success and prosperity in all its endeavours.

Thanking You,

Chetna Ana A

Chetna Anand





NURECA LIMITED

Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com Corporate Identification Number: L24304MH2016PLC320868

(Amount in INR million, unless otherwise stated) Statement of Unaudited Standalone Financial Results for the Quarter and Nine months ended 31 December 2024 Quarter ended Nine months ended Year ended 31 December 2024 31 December 2023 31 December 2023 30 September 2024 31 December 2024 31 March 2024 Sr. No. **Particulars** (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) 223.74 272.08 323.70 828.90 749.58 945.21 Revenue from operations Other income 15.18 32.09 59.21 105.42 118.13 105.64 2 3 867.71 1,050.85 282.95 Total income (1+2) 287.26 355.79 934.32 Expenses Purchase of stock-in-trade 208.97 178.83 104.53 556.11 503.73 631.90 Changes in inventories of stock-in-trade (16.51) 50.70 66.11 33.82 18.07 41.56 Employee benefits expense 36.00 33.91 31.05 103.74 86.57 115.66 Finance costs 1.41 2.52 1.01 5.21 2.89 4 60 22.42 Depreciation and amortization expense 4.93 5.73 5.62 16.78 16.78 238.24 204.94 267.40 Other expenses 90.94 86.81 66.33 Total expenses 325.74 358.50 274.65 953,90 832.98 1.083.54 Profit/(Loss) before income tax (3-4) (2.71) (38.48) 8.30 (19.58)34.73 (32.69) Tax expense (2.88) 5.07 11.72 8.87 13.98 13.52 - Current tax - Deferred tax charge/ (credit) (2.71) (1.05)(21.79) (1.32) (4.20)1.03 7 Profit/(Loss) after income tax (5-6) (32.89) 0.78 (27.40) 19.72 (24.42) (6.46)Other comprehensive income (i) Item that will not be reclassified to profit or loss 0.14 (0.19)0.40 (0.58)0.52 Α 0.13 (ii) Income tax relating to items that will not be (0 03) (0.04)0.05 (0.10)0.15 (0.13)reclassified to profit or loss В (i) Item that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss Other comprehensive income for the period (net 0.10 (0.14)0.30 (0.43)0,39 0.10 of tax) 9 Total comprehensive (loss)/income for the (32.79) (6.36) 0.64 (27.11) 19.29 (24.03) period (7+8) 10 Earning per share of Rs. 10 each (2.74) - Basic and diluted (in rupees) (not annualized) (3.29) (0 65) 0.08 1.97 (2.44)100.00 100.00 100.00 100 00 100 00 100.00 11 Paid-up equity share capital (Face value of share - Rs.10 each) Other equity 12 1.828.59 See accompanying notes to the unaudited standalone financial results





NURECA LIMITED

Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com Corporate Identification Number: L24304MH2016PLC320868

Notes to the Unaudited standalone financial results:

- The above unaudited standalone financial results for the quarter and nine months ended 31 December 2024 as reviewed by the Audit Committee, have been approved at the meeting of the Board of Directors held on 24 January 2025. The Limited review report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details, visit the investor relation section of our website www nureca com and financials results at corporate section at www.bseindia.com and www.nseindia.com.
- The business of the Company falls within single line of business i.e. business of home healthcare and wellness products. Accordingly, the segment related disclosures as per IND AS 108 are not applicable to the company.

For and on behalf of Board of Directors of

Nureca Limited

Place Muscat Date: 24 January 2025 Saurabh Goyal (Managing Director) DIN: 00136037

NURECA LIMITED



NURECA LIMITED

Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com Corporate Identification Number: L24304MH2016PLC320868

(Amount in INR million, unless otherwise stated)

	Quarter ended Nine Months ended Year ended						
	Particulars	31 December 2024 (Unaudited)	30 Septemeber 2024 (Unaudited)	31 December 2023 (Unaudited)	31 December 2024 (Unaudited)	31 December 2023 (Unaudited)	31 March 2024 (Audited)
1	Revenue from operations	264.63	311.89	223.74	779.21	749.58	919.2
2	Other income	14.77	31.71	59.01	104.42	117.73	105.
3	Total income (1+2)	279.40	343.60	282.75	883.63	867.31	1,024.
4	Expenses						
	Cost of material consumed	39.95	23.97	43.96	74.36	87.14	97
	Purchase of stock-in-trade	143.15	129.22	49.46	385.17	389.66	464
	Changes in inventories of stock-in-trade and finished goods	(17.79)	49.57	65.37	30.88	17.54	43
	Employee benefits expense	38.44	36.28	32.79	110.37	91.33	122
	Finance costs	1.75	2.69	1.10	5.94	3.10	4
	Depreciation and amortization expense	5.40	6.20	5.91	18.16	17.62	2:
	Other expenses	101.02	96.42	74.71	265.83	221.64	29
	Total expenses	311.92	344.35	273.30	890.71	828.03	1,049
5	Profit/(Loss) before income tax (3-4) Tax expense	(32.52)	(0.75)	9.45	(7.08)	39.28	(25
0	- Current tax	(1.99)	5.75	12.32	11.17	15.52	1
	- Deferred tax charge/(credit)	(2.52)			(2.04)		(2
7	Profit/(Loss) after income tax (5-6)	(28.01)	(4.82)	1.65	(16.21)	23.52	(1
8 A	Other comprehensive income (i) Item that will not be reclassified to profit or loss	0.13	0.14	(0.19)	0.40	(0.58)	
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.03)	(0 04)	0.05	(0.10)	0.15	,
В	(i) Item that will be reclassified to profit or loss	(0.06)	(0.02)	=	(0.08)	(0 02)	
	(ii) Income tax relating to items that will be reclassified to profit or loss		-			*	
	Other comprehensive income for the period (net of tax)	0.04	0.08	(0.14)	0.22	(0.45)	
9	Total comprehensive income/(loss) for the period (7+8)	(27.97)	(4.74)	1.51	(15.99)	23.07	(1
10	Earning per share of Rs. 10 each - Basic and diluted (in rupees) (not annualized)	(2.80)	(0.48)	0.16	(1.62)	2.35	
11	Paid-up equity share capital (Face value of share - Rs.10 each)	100.00	100.00	100.00	100.00	100.00	10
12	Other equity						1,83
	See accompanying notes to the unaudited consolidated financial results						



www.nureca.com

NURECA LIMITED

Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com Corporate Identification Number: L24304MH2016PLC320868

Notes to the unaudited consolidated financial results:

- 1 The above unaudited consolidated financial results for the quarter and nine months ended 31 December 2024 as reviewed by the Audit Committee, have been approved at the meeting of the Board of Directors held on 24 January 2025. The Limited review report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details, visit the investor relation section of our website www.nureca.com and financials results at corporate section at www.bseindia.com and www.nseindia.com.
- 2 The business of the Group falls within single line of business i e business of home healthcare and wellness products. Accordingly, the segment related disclosures as per IND AS 108 are not
- 3 The unaudited consolidated financial results include the financials results of the Parent company and its subsidiaries (collectively referred as 'the Group') as below

Parent Company Nureca Limited - Incorporated in india

Subsidiaries

i) Nureca Technologies Private Limited

ii) Nureca Healthcare Private Limited

iii) Nureca Inc. USA

For and on behalf of Board of Directors of Nureca Limited

> Saurabh Goyal (Managing Director) DIN 00136037

Place: Muscat Date: 24 January 2025

BSR&CollP

Chartered Accountants

Unit No. A505A 5th Floor, Elante Offices

Plot No. 178-178A, Industrial Area Phase - 1, Chandigarh - 160002

Tel: +91 172 672 3400

Limited Review Report on unaudited standalone financial results of Nureca Limited for the quarter ended 31 December 2024 and year to date results for the period from 1 April 2024 to 31 December 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Nureca Limited

- 1. We have reviewed the accompanying Statement of unaudited standalone financial results of Nureca Limited (hereinafter referred to as "the Company") for the quarter ended 31 December 2024 and year to date results for the period from 1 April 2024 to 31 December 2024 ("the Statement").
- 2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No.:101248W/W-100022

Ankush Goel

Digitally signed by Ankush Goel Date: 2025.01,24 16:38:18 +05'30'

Ankush Goel

Partner

Membership No.: 505121

UDIN:25505121BMLCOC5583

New Delhi 24 January 2025

BSR&Co.LLP

Chartered Accountants

Unit No. A505A 5th Floor, Elante Offices

Płot No. 178-178A, Industrial Area Phase - 1, Chandigarh – 160002

Tel: +91 172 672 3400

Limited Review Report on unaudited consolidated financial results of Nureca Limited for the quarter ended 31 December 2024 and year to date results for the period from 1 April 2024 to 31 December 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Nureca Limited

- 1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Nureca Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 31 December 2024 and year to date results for the period from 1 April 2024 to 31 December 2024 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
- 2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
 - We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.
- 4. The Statement includes the results of entities mentioned in Annexure I to this report.
- 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of the other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 6. We did not review the interim financial information of one Subsidiary included in the Statement, whose interim financial information reflects total revenues (before consolidation adjustments) of Rs. 65.81 million and Rs. 170.95 million, total net profit after tax (before consolidation adjustments) of Rs. 3.99 million and Rs. 10.38 million and total comprehensive income (before consolidation adjustments) of Rs.3.99 million and Rs. 10.38 million, for the quarter ended 31 December 2024 and for the period from 1 April 2024 to 31 December 2024 respectively, as considered in the Statement. This interim financial information has been reviewed by other auditor whose report has been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Limited Review Report (Continued)

Nureca Limited

Our conclusion is not modified in respect of this matter.

7. The Statement includes the financial information of two Subsidiaries which have not been reviewed, whose financial information reflect total revenues (before consolidation adjustments) of Rs. Nil and Rs. Nil, total net profit / (loss) after tax (before consolidation adjustments) of Rs. 0.25 million and total comprehensive income/ (loss) (before consolidation adjustments) of Rs. 0.25 million and Rs (0.31) million, for the quarter ended 31 December 2024 and for the period from 1 April 2024 and 31 December 2024 respectively, as considered in the Statement. According to the information and explanations given to us by the Parent's management, this interim financial information is not material to the Group.

Our conclusion is not modified in respect of this matter.

For BSR & Co. LLP

Chartered Accountants

Firm's Registration No.:101248W/W-100022

Ankush Goel Digitally signed by Ankush Goel Date: 2025.01.24 16:38:54 +05'30'

Ankush Goel

Partner

New Delhi

24 January 2025

Membership No.: 505121

UDIN:25505121BMLCOD9270

Limited Review Report (Continued) Nureca Limited

Annexure I

List of entities included in unaudited consolidated financial results.

Sr. No	Name of component	Relationship		
1	Nureca Limited	Holding Company (incorporated in India)		
2	Nureca INC	Subsidiary Company (incorporated in USA)		
3	Nureca Healthcare Private Limited	Subsidiary Company (incorporated in India)		
4	Nureca Technologies Private Limited	e Subsidiary Company (incorporated in India)		